ArticlemedRxiv : the preprint server for health sciences2025
Risk factors for West Nile neuroinvasive disease and mortality in the United States, 2013-2024.
Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Updated by
Authors and funding
2 authors.
Funding
Abstract
Importance: West Nile virus (WNV) is the leading mosquito-borne infection in the United States and can cause West Nile fever (WNF) or West Nile neuroinvasive disease (WNND), resulting in substantial morbidity and mortality. Contemporary risk factor analyses are needed to identify populations at increased risk for severe outcomes and target interventions accordingly. Objective: To assess risk factors for WNND and mortality among adults with WNV infection using a large national cohort from federated real-world data. Design: A retrospective cohort analysis from 2013-2024, consisting of de-identified electronic health record data from the TriNetX Research Network, including adult patients with an ICD-10 diagnosis consistent with WNV infection. Data were accessed from March 28 Setting: The retrospective cohort included patients from 65 healthcare organizations from across the United States, using the TriNetX Research Network. Participants: The overall initial cohort included 3,064 adult patients with an ICD-10 diagnosis consistent with WNV infection, including 1,328 with WNF and 1,206 with WNND. Exposures: Demographic characteristics (age, sex, race, ethnicity), comorbidities (hematologic malignancy, ischemic heart disease, other forms of heart disease, diabetes, HIV, chronic kidney disease (CKD), liver disease, hypertension, alcohol related disorders, cerebrovascular disease (CEVD), chronic obstructive pulmonary disease, asthma, multiple sclerosis, dementia, rheumatoid arthritis, organ transplant), and medications (immune suppressants, antineoplastics). Main Outcomes and Measures: The primary outcomes were the development of WNND and all-cause mortality (30-day, 90-day, and overall mortality). Results: Among all patients diagnosed with WNV infection, those with WNND were older (mean age 59 vs 55, p-value <0.0001) and more often male (61% vs 48%, p-value <0.0001). Significant risk factors for WNND included age (adjusted hazard ratio [aHR] 1.11 per decade, 95% confidence interval [CI] 1.06-1.49), male sex (aHR 1.29, 1.15-1.45), CKD (aHR 1.21, 1.002-1.45), CEVD (aHR 1.22, 1.03-1.45), hematologic malignancy (aHR 1.38, 1.09-1.76), immune suppressant use (aHR 1.43, 1.11-1.83), hypertension (aHR 1.18, 1.04-1.34), alcohol related disorders (aHR 1.54, 1.20-1.97), and multiple sclerosis (aHR 2.3, 1.62-3.37). Significant risk factors for mortality were WNND (aHR 2.49 for 30-day mortality, 95% CI 1.37-4.52), age (aHR 1.32 per decade, 95% CI 1.07-1.60), CKD (aHR 2.08, 95% CI 1.01-3.93), and CEVD (aHR 2.00, 95% CI 1.14-3.50). Conclusions and Relevance: Risk factors for WNND broadly reflect impaired immune response and/or central nervous system vulnerability. Patients who developed WNND were at substantially increased risk of death. Targeted prevention strategies and countermeasures for those at greatest risk for WNND could substantially reduce morbidity and mortality.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.